Pharmaceutical major Lupin's stock saw a rise, trading at ₹2116.45 on the BSE, marking an increase of 0.85% or 17.75 points from its previous close of ₹2098.70. The stock opened at ₹2098.05, with intraday highs and lows of ₹2126.85 and ₹2080.10, respectively. A total of 15,741 shares exchanged hands during the session.

Lupin's scrip, part of the BSE group 'A', carries a face value of ₹2 and previously reached a 52-week high of ₹2312.00 on September 5, 2024, and a low of ₹1200.35 on December 21, 2023. Over the past week, it traded between ₹2126.85 and ₹2040.00. The company's market capitalization stands at ₹96,551.93 crore, with promoters holding 46.96%, while institutions and non-institutional investors own 46.60% and 6.44%, respectively.

The rally follows Lupin receiving the USFDA’s nod for its Abbreviated New Drug Application (ANDA) for Emtricitabine and Tenofovir Alafenamide Tablets, 200 mg/25 mg, which are generic equivalents of Gilead Sciences' Descovy Tablets. As one of the first ANDA applicants, Lupin is eligible for 180 days of shared generic market exclusivity. The tablets will be manufactured at the company’s Nagpur facility.

Lupin continues to be a global leader in developing, producing, and marketing a broad spectrum of branded and generic formulations, biotech products, and active pharmaceutical ingredients (APIs).